BioNTech: Perbedaan antara revisi

Pada tahun 2020, BioNTech bermitra dengan [[Pfizer]] untuk pengujian dan logistik, dalam mengembangkan [[vaksin RNA]] [[vaksin COVID-19 Pfizer–BioNTech|BNT162b2]] untuk mencegah penularan [[COVID-19]]. Vaksin tersebut menawarkan efikasi sebesar 95% dalam mencegah terjadinya penularan COVID-19 setidaknya 7 hari setelah pemberian dosis kedua.<ref>{{cite report |title=Vaccines and Related Biological Products Advisory Committee Meeting December 10, 2020: FDA Briefing Document – Pfizer-BioNTech COVID-19 Vaccine |url=https://www.fda.gov/media/144245/download |access-date=2021-07-04 }}</ref> Pada tanggal 2 Desember 2020, otorisasi [[Human Medicines Regulations 2012|HMR]] sementara diterbitkan oleh Pemerintah Britania Raya untuk vaksinasi BNT162b2 di Britania Raya.<ref name="uk12-2a">{{cite web |title=Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine |url=https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/940728/Conditions_of_Authorisation_for_Pfizer_BioNTech_COVID-19_vaccine.pdf |date=2 December 2020 |publisher=Government of the United Kingdom |access-date=2 December 2020 |language=en}}</ref><ref name="uk12-2">{{cite web |title=UK medicines regulator gives approval for first UK COVID-19 vaccine |url=https://www.gov.uk/government/news/uk-medicines-regulator-gives-approval-for-first-uk-covid-19-vaccine |date=2 December 2020 |publisher=Government of the United Kingdom |access-date=2 December 2020 |language=en}}</ref> BNT162b2 adalah vaksin mRNA pertama yang diotorisasi. Beberapa hari kemudian, vaksin tersebut juga mendapat persetujuan darurat di Amerika Serikat,<ref>{{Citation|language=en|title=Pfizer-BioNTech COVID-19 Vaccine Frequently Asked Questions|url=https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/pfizer-biontech-covid-19-vaccine-frequently-asked-questions|access-date=22 December 2020}}</ref> Kanada,<ref>{{Citation|language=en|title=Pfizer-BioNTech COVID-19 vaccine: What you should know|date=9 December 2020|url=https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/pfizer-biontech.html|access-date=22 December 2020}}</ref>, dan [[Swiss]].<ref>{{Citation|language=en|title=Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland|url=https://www.swissmedic.ch/swissmedic/en/home/news/coronavirus-covid-19/covid-19-impfstoff_erstzulassung.html|access-date=22 December 2020}}</ref> Pada tanggal 21 Desember 2020, [[Komisi Eropa]] menyetujui vaksin koronavirus BioNTech/Pfizer sesuai rekomendasi positif dari [[European Medicines Agency]] (EMA).<ref>{{Cite web|date=21 December 2020|title=Commission approves BioNTech/Pfizer vaccine|url=https://www.politico.eu/article/european-commission-approves-biontech-pfizer-vaccine/|access-date=22 December 2020|website=Politico|language=en-US}}</ref>

BioNTech didirikan pada tahun 2008 berdasarkan riset dari [[Uğur Şahin]], [[Özlem Türeci]],<ref>{{Cite web|date=13 November 2020|title=BioNTech's founders: scientist couple in global spotlight|url=https://www.france24.com/en/live-news/20201113-biontech-s-founders-scientist-couple-in-global-spotlight|access-date=22 December 2020|publisher=France 24|language=en}}</ref>, dan Christoph Huber,<ref>{{Cite web|url=https://www.crunchbase.com/organization/biontech-ag/people|title = BioNTech – Employees, Board Members, Advisors & Alumni}}</ref> dengan investasi awal sebesar €150&nbsp;juta.<ref>{{Cite web|title=SEC Filing {{!}} BioNTech|url=https://investors.biontech.de/node/6751/html#toc|access-date=28 December 2020|website=investors.biontech.de}}</ref> Perusahaan ini fokus mengembangkan dan memproduksi teknologi dan obat untuk [[imunoterapi]] kanker individual.<ref name="SEC report" /> [[Andreas Strüngmann|Andreas]] dan [[Thomas Strüngmann]], [[Michael Motschmann]], serta [[Helmut Jeggle]] juga ikut mendirikan perusahaan ini.<ref name="france24">{{cite news |title=BioNTech's founders: scientist couple in global spotlight |url=https://www.france24.com/en/live-news/20201113-biontech-s-founders-scientist-couple-in-global-spotlight |access-date=7 December 2020 |publisher=France 24 |date=13 November 2020}}</ref> Pada tahun 2009, perusahaan ini mengakuisisi EUFETS dan JPT Peptide Technologies.<ref>{{Citation|language=en|url=https://www.biontech-imfs.de/news-events/news-post/news/eufets-becomes-biontech-innovative-manufacturing-services/|title=Eufets Becomes BioNTech Innovative Manufacturing Services|publisher=BioNTech IMFS|date=18 September 2017|access-date=11 November 2020}}</ref><ref>{{cite web |title=TheraCode to Acquire JPT Peptide Technologies |url=https://www.genomeweb.com/proteomics/theracode-acquire-jpt-peptide-technologies |publisher=GenomeWeb |access-date=7 December 2020 |date=11 May 2009}}</ref> [[Katalin Karikó]], yang karyanya mengenai mRNA saat bekerja di [[Universitas Pennsylvania]] mendukung pengembangan vaksin COVID-19 Pfizer–BioNTech,<ref>{{Cite web|date=2020-11-10|title=The story of mRNA: From a loose idea to a tool that may help curb Covid|url=https://www.statnews.com/2020/11/10/the-story-of-mrna-how-a-once-dismissed-idea-became-a-leading-technology-in-the-covid-vaccine-race/|access-date=2021-06-19|website=STAT|language=en-US}}</ref> pun bergabung ke BioNTech sebagai wakil presiden senior pada tahun 2013.<ref>{{Cite web|date=9 November 2020|title=Magyar kutató, hányatatott sorsú szabadalma is kellett a most bejelentett vakcinához {{!}} Forbes.hu|url=https://forbes.hu/uzlet/hanyatatott-sorsu-magyar-szabadalom-is-kellett-a-most-bejelentett-vakcinahoz/|access-date=22 December 2020|website=forbes.hu|language=hu}}</ref>